Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic plc

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Cardiovascular Operating Profit

Cardiovascular Operating Profit % Chg.

Cardiovascular Operating Profit Common Size

Neuroscience Operating Profit

Neuroscience Operating Profit % Chg.

Neuroscience Operating Profit Common Size

Medical Surgical Operating Profit

Medical Surgical Operating Profit % Chg.

Medical Surgical Operating Profit Common Size

Diabetes Operating Profit

Diabetes Operating Profit % Chg.

Diabetes Operating Profit Common Size

Other EBIT

Other EBIT % Chg.

Other EBIT Common Size

Total EBIT

Total EBIT Common Size

Total EBIT % Chg.

Cardiovascular Organic Revenue Growth

Cardiovascular Organic Revenue Growth % Chg.

Neuroscience Organic Revenue Growth

Neuroscience Organic Revenue Growth % Chg.

Medical Surgical Organic Revenue Growth

Medical Surgical Organic Revenue Growth % Chg.

Diabetes Organic Revenue Growth

Diabetes Organic Revenue Growth % Chg.

Total Organic Revenue Growth

Total Organic Revenue Growth % Chg.

Key Performance Indicators

U.S. Revenue

U.S. Revenue % Chg.

U.S. Revenue Common Size

Non-U.S. Developed Markets Revenue

Non-U.S. Developed Markets Revenue % Chg.

Non-U.S. Developed Markets Revenue Common Size

Emerging Markets Revenue

Emerging Markets Revenue % Chg.

Emerging Markets Revenue Common Size

Total International Revenue

Total International Revenue % Chg.

Total International Revenue Common Size

Other Revenue by Geography

Other Revenue by Geography % Chg.

Other Revenue by Geography Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Cardiac Rhythm & Heart Failure Revenue

Cardiac Rhythm & Heart Failure Revenue % Chg.

Cardiac Rhythm & Heart Failure Revenue Common Size

Structural Heart & Aortic Revenue

Structural Heart & Aortic Revenue % Chg.

Structural Heart & Aortic Revenue Common Size

Coronary & Peripheral Vascular Revenue

Coronary & Peripheral Vascular Revenue % Chg.

Coronary & Peripheral Vascular Revenue Common Size

Cardiovascular Revenue

Cardiovascular Revenue % Chg.

Cardiovascular Revenue Common Size

Cranial & Spinal Technologies Revenue

Cranial & Spinal Technologies Revenue % Chg.

Cranial & Spinal Technologies Revenue Common Size

Specialty Therapies Revenue

Specialty Therapies Revenue % Chg.

Specialty Therapies Revenue Common Size

Neuromodulation Revenue

Neuromodulation Revenue % Chg.

Neuromodulation Revenue Common Size

Neuroscience Revenue

Neuroscience Revenue % Chg.

Neuroscience Revenue Common Size

Surgical & Endoscopy Revenue

Surgical & Endoscopy Revenue % Chg.

Surgical & Endoscopy Revenue Common Size

Acute Care & Monitoring Revenue

Acute Care & Monitoring Revenue % Chg.

Acute Care & Monitoring Revenue Common Size

Medical Surgical Revenue

Medical Surgical Revenue % Chg.

Medical Surgical Revenue Common Size

Diabetes Revenue

Diabetes Revenue % Chg.

Diabetes Revenue Common Size

Other Segment Revenue

Other Segment Revenue % Chg.

Other Segment Revenue Common Size

Other Revenue

Other Revenue % Chg.

Other Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Other Segment Operating Profit

Other Segment Operating Profit % Chg.

Other Segment Operating Profit Common Size

Revenue	LTM	Apr '25	Apr '24
Cardiac Rhythm & Heart Failure Revenue	6,815	6,392	5,995
Structural Heart & Aortic Revenue	3,704	3,554	3,358
Coronary & Peripheral Vascular Revenue	2,575	2,535	2,478
Cardiovascular Revenue	13,094	12,481	11,831
Cranial & Spinal Technologies Revenue	5,102	4,973	4,756
Specialty Therapies Revenue	2,937	2,940	2,905
Neuromodulation Revenue	2,020	1,932	1,746
Neuroscience Revenue	10,056	9,846	9,406
Surgical & Endoscopy Revenue	6,596	6,498	6,508
Acute Care & Monitoring Revenue	1,943	1,909	1,908
Medical Surgical Revenue	8,538	8,407	8,417
Diabetes Revenue	2,900	2,755	2,488
Other Segment Revenue	170	137	221
Other Revenue	—	-89	1
Total Revenue	34,758	33,537	32,364

Revenue by Geography	LTM	Apr '25	Apr '24
U.S. Revenue	17,524	17,171	16,562
Non-U.S. Developed Markets Revenue	—	10,200	9,979
Emerging Markets Revenue	—	6,200	5,823
Total International Revenue	17,234	16,365	15,802
Other Revenue by Geography	—	1	—
Total Revenue by Geography	34,758	33,537	32,364

EBIT	LTM	Apr '25	Apr '24
Cardiovascular Operating Profit	4,217	4,801	4,474
Neuroscience Operating Profit	3,643	4,183	3,940
Medical Surgical Operating Profit	2,603	3,042	3,170
Diabetes Operating Profit	352	491	394
Other EBIT	-4,602	-6,562	-6,834
Total EBIT	6,213	5,955	5,144

Key Performance Indicators	LTM	Apr '25	Apr '24
Cardiovascular Organic Revenue Growth	—	6.3%	5%
Neuroscience Organic Revenue Growth	—	5.2%	5.2%
Medical Surgical Organic Revenue Growth	—	0.8%	4.7%
Diabetes Organic Revenue Growth	—	11.5%	8.6%
Total Organic Revenue Growth	—	4.9%	5.2%